Trademarkia Logo

Canada

C$
Trademark Search in Canada
ORELLIUM

View On IC.GC.CA

ORELLIUM
REGISTERED

on 11 Apr 2021

Last Applicant/ Owned by

Aurora Cannabis Enterprises Inc.

10104 - 103 Avenue NWSuite 2800Edmonton

ALBERTA

CA

T5J0H8

Serial Number

1882099 filed on 8th Feb 2018

Registration Number

TMA1097932 registered on 11th Apr 2021

Registration expiry Date

11th Apr 2031

Correspondent Address

FIELD LLP

213-304 Old Canmore RoadCanmore

ALBERTA

CA

T1W0L5

ORELLIUM

Trademark usage description

dried cannabis for the relief of pain and for alleviating symptoms experienced in the palliative care setting namely, intractable nausea and vomiting Read More

Classification Information

Class [004]
Industrial oils, greases and fuels

Comment text

CIPO Classification Code

Classification kind code

Nice

Class [005]
Cannabis related products, namely oils, salves, concentrated pastes and tinctures, each containing derivatives of cannabis, namely resins and oils, all the aforementioned products for the relief of pain and for alleviating symptoms experienced in the palliative care setting namely, intractable nausea and vomiting associated with chemotherapy or radiotherapy, anorexia, cachexia, severe intractable pain, severe depressed mood, and insomnia, for reducing stress and fatigue, for relief from nausea, vomiting, headaches, muscle spasms, seizures, wasting syndrome and loss of appetite in AIDS and cancer patients, for maintaining general health and well-being, for the relief of pain, for reducing stress and fatigue, for relieving anxiety, for relieving depression, as a sleep aid, for treating symptoms associated with anorexia nervosa, Crohn's disease, amyotrophic lateral sclerosis, fibromyalgia, spinal cord injury, epilepsy, migraines, arthritides and musculoskeletal disorders, neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, rheumatism, myasthenia gravis, Huntington's disease, amyotrophic lateral sclerosis, convulsant and movement disorders, cervical dystonia, Meige's syndrome, glaucoma, asthma, hypertension, mental illness, namely anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, attention and hyperactivity disorders, Alzheimer's disease, and dementia, for the treatment of, and symptoms associated with, skin infections and irritations, namely bacterial skin infections, dermatitis, atrophie blanche, eczema, burns, rashes from skin allergies and reactions, psoriasis, pruritis and neuropathic pain, for the treatment of, and relief of symptoms associated with, inflammatory diseases, namely inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, and inflammatory bowel diseases, diseases of the liver, Wilson's disease, metabolic syndrome, obesity, diabetes, diseases of the pancreas, and atherosclerosis, osteoarthritis, and osteoporosis, and for inhibiting and preventing the growth and spread of tumors and malignant cells, all the aforementioned products as anti-inflammatories, anti-viral enzyme activators, analgesics, sedatives, appetite stimulants and anti-emetics, anti-nauseants, intraocular pressure reducers, anti-tumors, antioxidants, antibacterials, antidepressants and antihypertensive; medicated soaps containing oils and resins derived from cannabis, medicated skin care preparations containing oils derived from cannabis, medicated skin care preparations containing resins derived from cannabis, bath additives and bath oils each containing oils and resins derived from cannabis, all the aforementioned products for the relief of pain and for alleviating symptoms experienced in the palliative care setting namely, intractable nausea and vomiting associated with chemotherapy or radiotherapy, anorexia, cachexia, severe intractable pain, severe depressed mood, and insomnia, for reducing stress and fatigue, for relief from nausea, vomiting, headaches, muscle spasms, seizures, wasting syndrome and loss of appetite in AIDS and cancer patients, for the relief of pain, for reducing stress and fatigue, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid, for treating symptoms associated with anorexia nervosa, Crohn's disease, amyotrophic lateral sclerosis, fibromyalgia, spinal cord injury, epilepsy, migraines, arthritides and musculoskeletal disorders, neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, rheumatism, myasthenia gravis, Huntington's disease, amyotrophic lateral sclerosis, convulsant and movement disorders, cervical dystonia, Meige's syndrome, glaucoma, asthma, hypertension, mental illness, namely anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, attention and hyperactivity disorders, Alzheimer's disease, and dementia, for the treatment of, and symptoms associated with, skin infections and irritations, namely bacterial skin infections, dermatitis, atrophie blanche, eczema, burns, rashes from skin allergies and reactions, psoriasis, pruritis and neuropathic pain, for the treatment of, and relief of symptoms associated with, inflammatory diseases, namely inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, and inflammatory bowel diseases, diseases of the liver, Wilson's disease, metabolic syndrome, obesity, diabetes, diseases of the pancreas, and atherosclerosis, osteoarthritis, and osteoporosis, and for inhibiting and preventing the growth and spread of tumors and malignant cells, and all the aforementioned products as antiinflammatories, anti-viral enzyme activators, analgesics, sedatives, appetite stimulants and anti-emetics, anti-nauseants, intraocular pressure reducers, anti-tumors, antioxidants, antibacterials, antidepressants and antihypertensives; personal sexual lubricants.

Classification kind code

11

Class [029]
Cannabis oil for food, for relaxation; cannabis oil for food, for mood enhancement

Classification kind code

11

Class [031]
Live cannabis plants

Classification kind code

11

Class [034]
Dried cannabis for relaxation; dried cannabis for mood enhancement; cannabis related products namely oils containing derivatives of cannabis, for relaxation; cannabis related products namely oils containing derivatives of cannabis, for mood enhancement; cannabis oil for electronic cigarettes, for relaxation; cannabis oil for electronic cigarettes, for mood enhancement; cannabis oil for oral vaporizers for smoking, for relaxation; cannabis oil for oral vaporizers for smoking, for mood enhancement; cannabidiol [CBD] oil for electronic cigarettes and for oral vaporizers for smoking, for relaxation; cannabidiol [CBD] oil for electronic cigarettes and for oral vaporizers for smoking, for mood enhancement; tetrahydrocannabinol [THC] oil for electronic cigarettes and for oral vaporizers for smoking, for relaxation; tetrahydrocannabinol [THC] oil for electronic cigarettes and for oral vaporizers for smoking, for mood enhancement;

Classification kind code

11

Class [039]
Providing the packaging of cannabis, cannabis related products, derivatives of cannabis and natural health products containing cannabis

Classification kind code

11

Class [044]
Providing the breeding, growing, cultivation, harvesting and production of cannabis

Classification kind code

11

Mark Details

Serial Number

1882099

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 135
on 20th Oct 2020		Amendment to Application
Submitted for opposition 42
on 25th Mar 2020		Advertised
Submitted for opposition 26
on 4th Mar 2020		Approved
Submitted for opposition 27
on 4th Mar 2020		Approval Notice Sent
Submitted for opposition 12
on 15th May 2019		Extension of Time
Submitted for opposition 22
on 31st Oct 2018		Search Recorded
Submitted for opposition 20
on 31st Oct 2018		Examiner's First Report
Submitted for opposition 31
on 13th Feb 2018		Formalized
Submitted for opposition 1
on 9th Feb 2018		Created
Submitted for opposition 30
on 8th Feb 2018		Filed